NY State Senate Bill 2025-S7668A

Current Bill Status - In Senate Committee Consumer Protection Committee

Introduced
- In Committee Assembly
- In Committee Senate
- On Floor Calendar Assembly
- On Floor Calendar Senate
- Passed Assembly
- Passed Senate
Delivered to Governor
Signed By Governor

Please enter your contact information

First Name

Last Name

Email Address

A valid email address is required.

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

View Actions

Date of Action	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Jan 07, 2026	referred to consumer protection
Jun 13, 2025	committed to rules
May 21, 2025	advanced to third reading amended 7668a
May 20, 2025	2nd report cal.
May 19, 2025	1st report cal.1135
Apr 28, 2025	referred to consumer protection

Votes

- May 19, 2025 - Consumer Protection Committee Vote
  S7668A
  
  Aye
  
  6
  
  Nay
  
  0
  
  Aye with Reservations
  
  0
  
  Absent
  
  0
  
  Excused
  
  1
  
  Abstained
  
  0
  - - Consumer Protection Committee Vote: May 19, 2025
      
      aye (6)
      
      Bynoe
      
      Canzoneri-Fitzpatrick
      
      Gonzalez
      
      May
      
      Ryan
      
      Weber
      
      excused (1)
      
      Myrie

Bill Amendments

Original

A (Active)

2025-S7668 - Details

Current Committee:: Senate Consumer Protection
Law Section:: General Business Law
Laws Affected:: Add §392-k, Gen Bus L
Versions Introduced in 2023-2024 Legislative Session:: S6084

2025-S7668 - Summary

Prohibits the knowing sale of xylazine above a certain weight to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

2025-S7668 - Sponsor Memo

                                 
BILL NUMBER: S7668

SPONSOR: FERNANDEZ
 
TITLE OF BILL:

An act to amend the general business law, in relation to prohibiting the
sale of xylazine above a certain weight

 
PURPOSE:

The purpose of this bill is to mitigate the dangers posed by the growing
misuse of xylazine, a powerful veterinary tranquilizer, in the illicit
drug supply. By regulating the sale, offer for sale, and delivery of
xylazine in New York State, this bill aims to protect public health,
prevent further contamination of street drugs, and create a funding
stream to support restorative efforts for those affected by substance
misuse.

 
SUMMARY OF PROVISIONS:

*Section 1: Defines "xylazine" as a pharmaceutical drug used for
sedation, anesthesia, muscle relaxation, and analgesia in non-human

mammals.

*Section 2: Prohibits the sale, offer for sale, or delivery of 50 grams
or more of xylazine to individuals without proof of its intended use for
institutional, veterinary, or scientific purposes.

*Section 3: Prohibits the sale, offer for sale, or delivery of 50 grams
or more of xylazine to individuals under the age of twenty-one.

*Section 4: Requires businesses to retain sales records, proof of age,
and proof of use from all purchasers of 50 grams or more of xylazine.

*Section 5: Establishes civil penalties for violations, with fines of up
to $3,000 for a first offense and $6,500 for each subsequent violation.
Directs all funds collected from penalties to be deposited into the New
York State Drug Treatment and Public Education Fund.

*Section 6: This act shall take effect immediately.

 
JUSTIFICATION:

New York State is currently experiencing an opioid epidemic that has
been worsened by the introduction of dangerous additives such as xyla-
zine into the illicit drug supply. Traditional mitigation strategies-
such as drug scheduling or the criminalization of low-level drug users-
have proven ineffective. Xylazine, a tranquilizer intended strictly for
veterinary use, is increasingly found in street drugs, especially those
mixed with synthetic opioids like fentanyl.

This combination is particularly dangerous because xylazine does not
respond to naloxone, the standard opioid overdose reversal agent.

Xylazine causes severe complications in humans, including respiratory
depression and extreme skin ulcers that lead to tissue decay, bacterial
infections, and even amputation. According to the Centers for Disease
Control and Prevention (CDC), the presence of xylazine in drug-poisoning
deaths rose by 1,238% from 2018 to 2021. In 2023, xylazine was found in
over 25% of drug samples tested in New York City, though experts believe
the actual prevalence is higher.

Rather than relying on punitive or regressive approaches, this bill
regulates the supply side of the problem by targeting large-scale sales
of xylazine-specifically quantities of 50 grams or more-and requiring
that such sales be documented and restricted to appropriate uses. Civil
penalties are imposed on violators, and these fines are directed into a
fund that supports treatment, public education, and harm reduction
services.

In drafting this bill, care was taken to protect legitimate veterinary
and scientific use of xylazine. The bill is a balanced and proactive
step to prevent this dangerous substance from worsening the opioid
crisis, while ensuring resources are available to support those affected
by substance misuse.

 
FISCAL IMPLICATIONS:

None.

 
EFFECTIVE DATE:
This act shall take effect immediately.

2025-S7668 - Bill Text download pdf

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   7668
 
                        2025-2026 Regular Sessions
 
                             I N  S E N A T E
 
                              April 28, 2025
                                ___________
 
 Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when
   printed to be committed to the Committee on Consumer Protection
 
 AN ACT to amend the general business law, in relation to prohibiting the
   sale of xylazine above a certain weight
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. The general business law is amended by adding a new section
 392-k to read as follows:
   § 392-K. SALE OF XYLAZINE. 1. FOR PURPOSES OF THIS SECTION,  THE  TERM
 "XYLAZINE"  SHALL  MEAN  A  PHARMACEUTICAL DRUG USED FOR SEDATION, ANES-
 THESIA, MUSCLE RELAXATION, AND ANALGESIA  IN  ANIMALS  SUCH  AS  HORSES,
 CATTLE, AND OTHER NON-HUMAN MAMMALS.
   2.  THE PROVISIONS OF THIS SECTION SHALL APPLY ONLY TO THE SALE, OFFER
 FOR SALE, DELIVERY, OR DISTRIBUTION OF XYLAZINE IN QUANTITIES  OF  FIFTY
 GRAMS OR MORE.
   3.  NO  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY, FIRM,
 ONLINE PLATFORM, OR ANY OTHER BUSINESS ENTITY DOING BUSINESS WITHIN THIS
 STATE SHALL KNOWINGLY SELL, OFFER FOR SALE, OR DELIVER  FIFTY  GRAMS  OR
 MORE  OF  XYLAZINE  TO INDIVIDUALS WITHOUT PROOF OF ITS INTENDED USE FOR
 INSTITUTIONAL, VETERINARY, OR SCIENTIFIC PURPOSES.
   4. NO  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY,  FIRM,
 ONLINE  PLATFORM,  OR  OTHER  BUSINESS ENTITY DOING BUSINESS WITHIN THIS
 STATE SHALL KNOWINGLY SELL, OFFER FOR SALE, OR DELIVER  FIFTY  GRAMS  OR
 MORE OF XYLAZINE TO INDIVIDUALS UNDER THE AGE OF TWENTY-ONE.
   5.  ANY  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY COMPANY, FIRM,
 ONLINE PLATFORM, OR OTHER BUSINESS ENTITY  DOING  BUSINESS  WITHIN  THIS
 STATE WHICH KNOWINGLY SELLS, OFFERS FOR SALE, OR DISTRIBUTES FIFTY GRAMS
 OR  MORE  OF  XYLAZINE, SHALL REQUIRE AND RETAIN SALES RECORDS, PROOF OF
 AGE, AND PROOF OF USE FROM ALL PURCHASERS.
   6. ANY CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY,  FIRM,
 ONLINE  PLATFORM,  OR  OTHER  BUSINESS ENTITY DOING BUSINESS WITHIN THIS
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD02623-05-5

 S. 7668                             2
 
 STATE THAT VIOLATES THE PROVISIONS OF THIS SECTION BY KNOWINGLY SELLING,
 OFFERING FOR SALE, OR DELIVERING FIFTY GRAMS OR MORE OF  XYLAZINE  SHALL
 BE  SUBJECT  TO  A CIVIL PENALTY OF NOT MORE THAN THREE THOUSAND DOLLARS
 FOR  A  FIRST  VIOLATION, AND SIXTY-FIVE HUNDRED DOLLARS FOR EACH SUBSE-
 QUENT VIOLATION, RECOVERABLE IN AN ACTION BY THE ATTORNEY GENERAL OF THE
 STATE OF NEW YORK.  ALL FUNDS COLLECTED OR RECEIVED BY  THE  STATE  FROM
 CIVIL PENALTIES IMPOSED UNDER THIS SECTION SHALL BE DEPOSITED IN THE NEW
 YORK STATE DRUG TREATMENT AND PUBLIC EDUCATION FUND ESTABLISHED PURSUANT
 TO SECTION NINETY-NINE-JJ OF THE STATE FINANCE LAW.
   § 2. This act shall take effect immediately.

2025-S7668A (ACTIVE) - Details

Current Committee:: Senate Consumer Protection
Law Section:: General Business Law
Laws Affected:: Add §392-k, Gen Bus L
Versions Introduced in 2023-2024 Legislative Session:: S6084

2025-S7668A (ACTIVE) - Summary

Prohibits the knowing sale of xylazine above a certain weight to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

2025-S7668A (ACTIVE) - Sponsor Memo

                                 
BILL NUMBER: S7668A

SPONSOR: FERNANDEZ
 
TITLE OF BILL:

An act to amend the general business law, in relation to prohibiting the
sale of xylazine above a certain weight

 
PURPOSE:

The purpose of this bill is to mitigate the dangers posed by the growing
misuse of xylazine, a powerful veterinary tranquilizer, in the illicit
drug supply. By regulating the sale, offer for sale, and delivery of
xylazine in New York State, this bill aims to protect public health,
prevent further contamination of street drugs, and create a funding
stream to support restorative efforts for those affected by substance
misuse.

 
SUMMARY OF PROVISIONS:

*Section 1: Defines "xylazine" as a pharmaceutical drug used for
sedation, anesthesia, muscle relaxation, and analgesia in non-human

mammals.

*Section 2: Prohibits the sale, offer for sale, or delivery of 50 grams
or more of xylazine to individuals without proof of its intended use for
institutional, veterinary, or scientific purposes.

*Section 3: Prohibits the sale, offer for sale, or delivery of 50 grams
or more of xylazine to individuals under the age of twenty-one.

*Section 4: Requires businesses to retain sales records, proof of age,
and proof of use from all purchasers of 50 grams or more of xylazine.

*Section 5: Establishes civil penalties for violations, with fines of up
to $3,000 for a first offense and $6,500 for each subsequent violation.
Directs all funds collected from penalties to be deposited into the New
York State Drug Treatment and Public Education Fund.

*Section 6: This act shall take effect immediately.

 
JUSTIFICATION:

New York State is currently experiencing an opioid epidemic that has
been worsened by the introduction of dangerous additives such as xyla-
zine into the illicit drug supply. Traditional mitigation strategies-
such as drug scheduling or the criminalization of low-level drug users-
have proven ineffective. Xylazine, a tranquilizer intended strictly for
veterinary use, is increasingly found in street drugs, especially those
mixed with synthetic opioids like fentanyl. This combination is partic-
ularly dangerous because xylazine does not respond to naloxone, the
standard opioid overdose reversal agent.

Xylazine causes severe complications in humans, including respiratory
depression and extreme skin ulcers that lead to tissue decay, bacterial
infections, and even amputation. According to the Centers for Disease
Control and Prevention (CDC), the presence of xylazine in drug poisoning
deaths rose by 1,238% from 2018 to 2021. In 2023, xylazine was found in

over 25% of drug samples tested in New York City, though experts believe
the actual prevalence is higher.

Rather than relying on punitive or regressive approaches, this bill
regulates the supply side of the problem by targeting large-scale sales
of xylazine-specifically quantities of 50 grams or moreand requiring
that such sales be documented and restricted to appropriate uses. Civil
penalties are imposed on violators, and these fines are directed into a
fund that supports treatment, public education, and harm reduction
services.

In drafting this bill, care was taken to protect legitimate veterinary
and scientific use of xylazine. The bill is a balanced and proactive
step to prevent this dangerous substance from worsening the opioid
crisis, while ensuring resources are available to support those affected
by substance misuse.

 
FISCAL IMPLICATIONS:

None.

 
EFFECTIVE DATE:
This act shall take effect immediately.

2025-S7668A (ACTIVE) - Bill Text download pdf

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  7668--A
     Cal. No. 1135
 
                        2025-2026 Regular Sessions
 
                             I N  S E N A T E
 
                              April 28, 2025
                                ___________
 
 Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when
   printed  to  be  committed  to the Committee on Consumer Protection --
   reported favorably from said committee, ordered to  first  and  second
   report,  amended  on second report, ordered to a third reading, and to
   be reprinted as amended, retaining its place in  the  order  of  third
   reading
 
 AN ACT to amend the general business law, in relation to prohibiting the
   sale of xylazine above a certain weight
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. The general business law is amended by adding a new section
 392-k to read as follows:
   § 392-K. SALE OF XYLAZINE. 1. FOR PURPOSES OF THIS SECTION,  THE  TERM
 "XYLAZINE"  SHALL  MEAN  A  PHARMACEUTICAL DRUG USED FOR SEDATION, ANES-
 THESIA, MUSCLE RELAXATION, AND ANALGESIA  IN  ANIMALS  SUCH  AS  HORSES,
 CATTLE, AND OTHER NON-HUMAN MAMMALS.
   2.  THE PROVISIONS OF THIS SECTION SHALL APPLY ONLY TO THE SALE, OFFER
 FOR SALE, DELIVERY, OR DISTRIBUTION OF XYLAZINE IN QUANTITIES  OF  FIFTY
 GRAMS OR MORE PER OCCURRENCE.
   3.  NO  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY, FIRM,
 ONLINE PLATFORM, OR ANY OTHER BUSINESS ENTITY DOING BUSINESS WITHIN THIS
 STATE SHALL KNOWINGLY SELL, OFFER FOR SALE, OR DELIVER  FIFTY  GRAMS  OR
 MORE  OF  XYLAZINE  TO INDIVIDUALS WITHOUT PROOF OF ITS INTENDED USE FOR
 INSTITUTIONAL, VETERINARY, OR SCIENTIFIC PURPOSES.
   4. NO  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY,  FIRM,
 ONLINE  PLATFORM,  OR  OTHER  BUSINESS ENTITY DOING BUSINESS WITHIN THIS
 STATE SHALL KNOWINGLY SELL, OFFER FOR SALE, OR DELIVER  FIFTY  GRAMS  OR
 MORE OF XYLAZINE TO INDIVIDUALS UNDER THE AGE OF TWENTY-ONE.
   5.  ANY  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY COMPANY, FIRM,
 ONLINE PLATFORM, OR OTHER BUSINESS ENTITY  DOING  BUSINESS  WITHIN  THIS
 STATE WHICH KNOWINGLY SELLS, OFFERS FOR SALE, OR DISTRIBUTES FIFTY GRAMS
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.

                                                            LBD02623-06-5
 S. 7668--A                          2
 
 OR  MORE  OF  XYLAZINE, SHALL REQUIRE AND RETAIN SALES RECORDS, PROOF OF
 AGE, AND PROOF OF USE FROM ALL PURCHASERS.
   6.  ANY  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY COMPANY, FIRM,
 ONLINE PLATFORM, OR OTHER BUSINESS ENTITY  DOING  BUSINESS  WITHIN  THIS
 STATE THAT VIOLATES THE PROVISIONS OF THIS SECTION BY KNOWINGLY SELLING,
 OFFERING  FOR  SALE, OR DELIVERING FIFTY GRAMS OR MORE OF XYLAZINE SHALL
 BE SUBJECT TO A CIVIL PENALTY OF NOT MORE THAN  THREE  THOUSAND  DOLLARS
 FOR  A  FIRST  VIOLATION, AND SIXTY-FIVE HUNDRED DOLLARS FOR EACH SUBSE-
 QUENT VIOLATION, RECOVERABLE IN AN ACTION BY THE ATTORNEY GENERAL OF THE
 STATE OF NEW YORK.  ALL FUNDS COLLECTED OR RECEIVED BY  THE  STATE  FROM
 CIVIL PENALTIES IMPOSED UNDER THIS SECTION SHALL BE DEPOSITED IN THE NEW
 YORK STATE DRUG TREATMENT AND PUBLIC EDUCATION FUND ESTABLISHED PURSUANT
 TO SECTION NINETY-NINE-JJ OF THE STATE FINANCE LAW.
   §  2.  This  act shall take effect on the ninetieth day after it shall
 have become a law.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Find your Senator and share your views on important issues.

Do you support this bill?

Senate Bill S7668A

Sponsored By

Current Bill Status - In Senate Committee Consumer Protection Committee

Actions

Votes

May 19, 2025 - Consumer Protection Committee Vote

Consumer Protection Committee Vote: May 19, 2025

Bill Amendments

2025-S7668 - Details

2025-S7668 - Summary

2025-S7668 - Sponsor Memo

2025-S7668 - Bill Text download pdf

2025-S7668A (ACTIVE) - Details

2025-S7668A (ACTIVE) - Summary

2025-S7668A (ACTIVE) - Sponsor Memo

2025-S7668A (ACTIVE) - Bill Text download pdf

Comments

Do you support this bill?

Get Status Alerts for 2025-S7668A

Senate Bill S7668A

Share this bill

Sponsored By

Nathalia Fernandez

Current Bill Status - In Senate Committee Consumer Protection Committee

Actions

Votes

Bill Amendments

2025-S7668 - Details

2025-S7668 - Summary

2025-S7668 - Sponsor Memo

2025-S7668 - Bill Text download pdf

2025-S7668A (ACTIVE) - Details

2025-S7668A (ACTIVE) - Summary

2025-S7668A (ACTIVE) - Sponsor Memo

2025-S7668A (ACTIVE) - Bill Text download pdf

Comments